Loading...
Loading...
Bristol-Myers
Squibb Company
BMY today announced four- and five-year
survival rates based on long-term follow up from Phase 3 and Phase 2
YERVOY® (ipilimumab) clinical trials in patients with
treatment-naïve and previously-treated metastatic melanoma. The data
were presented at the ESMO 2012 Congress (European Society for Medical
Oncology). (Abstract #1127 and 1116.)
In the Phase 3 trial (024), patients who had not previously received
treatment for metastatic melanoma (n=502) were randomized to receive
either the investigational dose of YERVOY 10 mg/kg in combination with
dacarbazine (DTIC, 850 mg/m2) or DTIC alone. Long-term
follow-up from this study demonstrated that treatment with YERVOY plus
DTIC resulted in a four-year survival
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in